Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Identifieur interne : 003468 ( Istex/Curation ); précédent : 003467; suivant : 003469Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Auteurs : Penelope Hogarth [États-Unis] ; Luca Lovrecic [États-Unis] ; Dimitri Krainc [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-10-15.
English descriptors
Abstract
Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21632
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003468
Links to Exploration step
ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lovrecic, Luca" sort="Lovrecic, Luca" uniqKey="Lovrecic L" first="Luca" last="Lovrecic">Luca Lovrecic</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Krainc, Dimitri" sort="Krainc, Dimitri" uniqKey="Krainc D" first="Dimitri" last="Krainc">Dimitri Krainc</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21632</idno>
<idno type="url">https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003468</idno>
<idno type="wicri:Area/Istex/Curation">003468</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Oregon Health & Science University, Portland, Oregon</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lovrecic, Luca" sort="Lovrecic, Luca" uniqKey="Lovrecic L" first="Luca" last="Lovrecic">Luca Lovrecic</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Krainc, Dimitri" sort="Krainc, Dimitri" uniqKey="Krainc D" first="Dimitri" last="Krainc">Dimitri Krainc</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-10-15">2007-10-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="1962">1962</biblScope>
<biblScope unit="page" to="1964">1964</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">6FF31B34BBC74B3B9081F504D87EED5D30419A26</idno>
<idno type="DOI">10.1002/mds.21632</idno>
<idno type="ArticleID">MDS21632</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term>
<term>histone deacetylase inhibitor</term>
<term>sodium phenylbutyrate</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26 |texte= Sodium phenylbutyrate in Huntington's disease: A dose‐finding study }}
This area was generated with Dilib version V0.6.23. |